BNIPL-2 Inhibitors
BNIPL-2 inhibitors encompass a diverse group of chemical compounds that exert their inhibitory action through various intracellular signaling pathways, ultimately converging on the diminishment of BNIPL-2 activity. For instance, PD 98059 and U0126 target the MEK1/2 enzymes, preventing the activation of the MAPK/ERK kinase pathway, which is a crucial route for BNIPL-2's involvement in cellular proliferation and survival responses. When MEK is inhibited, the subsequent decrease in ERK phosphorylation leads to reduced BNIPL-2 activity. Similarly, LY 294002 and Wortmannin are potent PI3K inhibitors; their blockade of the PI3K/Akt pathway results in downregulation of survival and growth signals that BNIPL-2 might influence. Rapamycin's inhibition of mTOR, a downstream target of PI3K/Akt, further exemplifies the multi-tiered approach of these inhibitors, all aiming to reduce BNIPL-2's functional activity by curtailing upstream signaling processes.
Continuing with this theme, SP600125's inhibition of JNK signaling, Dasatinib's blockade of Src family kinases, and Sorafenib's targeting of RAF, VEGFR, and PDGFR kinases represent targeted interventions that, by modulating specific kinase activities, indirectly lead to decreased BNIPL-2 action, given its potential regulatory roles downstream. Direct cyclin-dependent kinase inhibition by Roscovitine and the alteration of p53 activity by Nutlin-3, which stabilizes p53 and activates its downstream signaling, can also result in reduced BNIPL-2 activity, particularly if BNIPL-2 is implicated in cell cycle control or p53-dependent pathways. Lastly, Gefitinib's EGFR tyrosine kinase inhibition can interrupt growth factor signaling, presenting another mechanism by which the activity of BNIPL-2 can be diminished, highlighting the multifaceted strategies employed by BNIPL-2 inhibitors to achieve their functional suppression.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 is a selective inhibitor of MEK which prevents the activation of MAPK/ERK kinase. BNIPL-2, associated with the ERK pathway, has its activity diminished as ERK phosphorylation is inhibited, reducing BNIPL-2's functional participation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY 294002 is a phosphoinositide 3-kinases (PI3K) inhibitor which blocks the PI3K/Akt pathway. This inhibition downstream leads to the decreased activity of BNIPL-2, which is implicated in pathways regulated by PI3K signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB 203580 is a specific inhibitor of p38 MAP kinase. The inhibition of p38 MAPK can diminish the activity of BNIPL-2 by reducing the phosphorylation of proteins involved in the same signaling cascades as BNIPL-2. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is an inhibitor of PI3K, which diminishes Akt phosphorylation and subsequent signaling pathways. BNIPL-2, with roles in these signaling cascades, experiences reduced activity as a result of this inhibition. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, a key kinase in the PI3K/Akt pathway. The inhibition of mTOR can lead to a decrease in BNIPL-2 activity, given BNIPL-2's involvement in signaling pathways that are controlled by mTOR. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, leading to diminished JNK signaling. As BNIPL-2 is involved in cellular processes regulated by JNK activity, this inhibition can lead to reduced BNIPL-2 activity. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a Src family kinase inhibitor, and by diminishing Src kinase activity, it can indirectly lead to reduced activity of BNIPL-2 if BNIPL-2 is involved in signaling pathways or cellular processes regulated by Src kinase. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $94.00 $265.00 | 42 | |
Roscovitine is an inhibitor of cyclin-dependent kinases (CDKs). By reducing CDK activity, it can indirectly decrease BNIPL-2 activity if BNIPL-2's function is linked to the cell cycle or processes modulated by CDKs. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib is a kinase inhibitor with targets including RAF, VEGFR, and PDGFR. By inhibiting these kinases, sorafenib can indirectly diminish BNIPL-2 activity if BNIPL-2 is associated with signaling pathways involving these kinases. | ||||||
Nutlin-3 | 548472-68-0 | sc-45061 sc-45061A sc-45061B | 1 mg 5 mg 25 mg | $62.00 $225.00 $779.00 | 24 | |
Nutlin-3 disrupts the interaction between p53 and MDM2, leading to stabilization and activation of p53. If BNIPL-2 activity is modulated by p53-mediated signaling, the stabilization of p53 by Nutlin-3 can lead to a decrease in BNIPL-2 activity. | ||||||